Elucidating the Molecular Mechanism of TRIP13-mediated Radiation Resistance in Oral Squamous Cell Carcinoma
Elucidating the Molecular Mechanism of TRIP13-mediated Radiation Resistance in Oral Squamous Cell Carcinoma
批准号:
10649402
负责人:
Marsha-Kay Norissa Deanna Hutchinson
金额:
$5.35万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2025-06-30
关键词:
ATP phosphohydrolaseATPase DomainAddressAntibodiesAttenuatedBindingBiologicalCell LineCell SurvivalCetuximabComplexDNADNA DamageDNA-dependent protein kinaseDataDiseaseDouble Strand Break RepairEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExposure toFDA approvedFailureGenetic EngineeringGoalsHuman Cell LineHydrolysisImmunohistochemistryImpairmentIn VitroIncidenceInvestigationKnowledgeLaboratoriesMalignant Epithelial CellMalignant NeoplasmsMediatingModalityMolecularMusMutationNonhomologous DNA End JoiningOncogenicPathway interactionsPatient-Focused OutcomesPatientsPeptidesPhosphorylationPilot ProjectsProteinsRIPK1 geneRadiationRadiation Induced DNA DamageRadiation ToleranceRadiation induced double strand breakRadiation therapyRadiation-Sensitizing AgentsRecurrenceRecurrent tumorRoleSiteSurvival RateTestingThyroid Hormone ReceptorWestern BlottingWorkadvanced diseaseaggressive therapycytotoxicgenetically modified cellsimprovedin vivoinsightirradiationmouth squamous cell carcinomaneoplastic cellnovelnovel strategiesoverexpressionpatient prognosispredictive markerradiation resistanceradiation responseradioresistantrepairedtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Oral squamous cell carcinoma (OSCC) is a common and aggressive cancer. In recent years, despite significant
effort to understand the pathobiology of the disease, there has been only marginal improvement in patient
prognosis. Radiation is one of the chief treatment modalities for OSCC, but radiation resistance has led to a high
incidence of locoregional failure and tumor recurrence. Radiation is incredibly cytotoxic and has the potential to
completely annihilate tumors via induction of lethal double strand breaks (DSBs) in DNA. To adequately exploit
the benefits of radiation and improve patient outcomes, a thorough understanding of the molecular mechanisms
of radiation resistance is essential. Non-homologous end joining (NHEJ) is the main repair pathway for radiation-
induced DSBs. The high incidence of locoregional failure and tumor recurrence after radiation is likely a reflection
of efficient repair. Therefore, a keen understanding of how NHEJ occurs is vital to developing novel strategies to
increase radiation sensitivity. Our laboratory identified thyroid hormone receptor interacting protein 13 (TRIP13)
as an oncogenic ATPase that promotes NHEJ and radiation resistance in OSCC. The goal of this study is to
delineate the molecular mechanism of TRIP13-mediated NHEJ that enhances radiation resistance. Pilot data
show that phosphorylation of TRIP13 is essential for radioresistance. Moreover, loss of the ATPase activity of
TRIP13 sensitizes OSCC to radiation; ATPases are frequently involved in assembly of biological complexes.
Therefore, the central hypothesis of the proposed study is that phosphorylation-induced ATPase activity of
TRIP13 is necessary for DNA-PK complex formation in NHEJ, thereby promoting radiation resistance in OSCC.
To test this hypothesis, we propose the following specific aims: 1) to explore the extent to which phosphorylation
of TRIP13 promotes NHEJ via induction of its ATPase activity; 2) to investigate the extent to which the ATPase
activity of TRIP13 promotes radiation resistance and 3) to validate pTRIP13 as a predictive marker of radiation
resistance. To address these aims, we will engineer genetically modified cell lines to dissect the mechanism of
radiation resistance in vitro and in in vivo. These aims will elucidate the molecular mechanism behind TRIP13-
mediated radiation resistance and will investigate phospho-TRIP13 as a novel predictive marker of radiation
resistance.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Elucidating the Molecular Mechanism of TRIP13-mediated Radiation Resistance in Oral Squamous Cell Carcinoma
-
批准号:10480747
-
项目类别:
-
资助金额:$5.26万
-
财政年份:2021
-
负责人:Marsha-Kay Norissa Deanna Hutchinson
-
依托单位:
海外基金